Transcriptomic cohort analysis reveals limited external prognostic reproducibility of a four-gene hypoxia signature in esophageal squamous cell carcinoma, indicating the need for prospective...
Background Hypoxia-associated transcription is an important component of the esophageal squamous cell carcinoma (ESCC) microenvironment. We developed an exploratory four-gene signature and evaluated its prognostic performance, internal stability, cross-cohort transferability, and biological context. Methods TCGA, GTEx, and GEO transcriptomic data were analyzed. A four-gene signature was derived using univariate Cox screening, 10-fold cross-validated LASSO Cox regression, and stepwise multivariable Cox regression. Internal validation used 1,000 bootstrap resamples, optimism correction, and out-of-bag calibration. Fixed-coefficient external survival testing was conducted in GSE53624 and GSE53622. We additionally audited clinical heterogeneity across cohorts, performed exploratory continuous-score subgroup Cox analyses and interaction tests, and synthesized 16 reviewer-directed hypoxia-associated pathways using the original database-wide FDR values. TCGA-only differential-expression sensitivity, paired GSE23400 expression, patient/sample-level GSE160269 single-cell, immune functional scoring, and exploratory in silico drug-sensitivity analyses were also performed. Results The signature comprised ATF3, EGFR, KDELR3, and PNRC1 in 91 ESCC patients. High-risk patients had poorer overall survival (log-rank P = 0.0031), but the complete feature-selection pipeline was unstable under bootstrap resampling. Apparent 1-, 3-, and 5-year AUCs were 0.730, 0.696, and 0.567; optimism-corrected AUCs were 0.691, 0.657, and 0.546, respectively, and the corrected C-index was 0.660. Direct application in GSE53624 ( n = 119) and GSE53622 ( n = 60) did not reproduce derivation-cohort performance. TNM-stage and follow-up distributions differed across cohorts, and TCGA treatment data were unavailable. Exploratory subgroup analyses did not demonstrate consistent external performance. Focused GSEA identified heterogeneous directions across hypoxia-adjacent inflammatory, angiogenic, metabolic, and redox processes. Conclusion The four-gene signature showed moderate short-term discrimination in the derivation cohort but weak long-term performance, selection instability, and limited cross-cohort reproducibility. It should be regarded as a hypothesis-generating research signature rather than a platform-independent or clinically deployable model, and requires prospective multicenter and experimental validation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: